Oncology

TurningComplexity into Clarity

Cancer is not a single disease—it's a highly complex and dynamic group of disorders, often driven by a multitude of genomic alterations. Despite advancements in treatment, many patients still face uncertainty due to incomplete or delayed molecular diagnoses.

1 / 4

Operify Hereditary Cancer Panel

About 5-10% of all cancers are linked to inherited genetic mutations, often going undetected until late stages or after multiple family members are affected.
The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), Neurofibromatosis (NF) etc.
Early identification of germline mutations enables proactive clinical decisions, including risk-reducing strategies, targeted surveillance, and family cascade testing.
Studies show that genetic testing in hereditary cancer cases improves outcomes and informs care for both patients and at-risk relatives.

Key Features

Comprehensive Gene Coverage

Includes high- and moderate-risk genes such as BRCA1, BRCA2, TP53, MLH1, MSH2, APC, and others.

Germline Variant Detection

Accurately detects SNVs, Indels, and selected CNVs in genes associated with inherited cancer risk.

Family-Centered Testing

Supports cascade testing for at-risk relatives, enabling early detection and prevention.

Clinical Actionability

Provides insights that guide surveillance, preventive measures, and personalized treatment planning.

High Sensitivity & Specificity

Uses ≥100X sequencing depth with ≥90% Q30 base quality for reliable variant calling.

Expert Interpretation & Reporting

Variants classified using ACMG guidelines, backed by curated literature and clinical databases.

Sample Requirements

Turnaround Time

21 Days

Sample Requirement

Blood/Saliva/Cheek Swab/Genomic DNA/Dry Blood Spot